Commonwealth Equity Services LLC Sells 2,155 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Commonwealth Equity Services LLC cut its holdings in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT – Get Rating) by 2.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 81,055 shares of the company’s stock after selling 2,155 shares during the period. Commonwealth Equity Services LLC owned about 0.33% of ClearPoint Neuro worth $686,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Advisor Group Holdings Inc. increased its holdings in ClearPoint Neuro by 131.5% in the first quarter. Advisor Group Holdings Inc. now owns 2,153 shares of the company’s stock valued at $66,000 after purchasing an additional 1,223 shares during the period. Tower Research Capital LLC TRC acquired a new stake in ClearPoint Neuro in the third quarter valued at $88,000. Envestnet Asset Management Inc. acquired a new stake in ClearPoint Neuro in the first quarter valued at $106,000. Bank of New York Mellon Corp acquired a new stake in ClearPoint Neuro in the third quarter valued at $110,000. Finally, Jane Street Group LLC acquired a new stake in ClearPoint Neuro in the third quarter valued at $134,000. 15.11% of the stock is currently owned by institutional investors.

ClearPoint Neuro Price Performance

Shares of NASDAQ CLPT opened at $7.91 on Thursday. ClearPoint Neuro, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $16.96. The stock has a market cap of $194.43 million, a price-to-earnings ratio of -10.69 and a beta of 1.14. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.98 and a current ratio of 7.60. The firm’s 50-day simple moving average is $9.05 and its 200 day simple moving average is $9.03.

ClearPoint Neuro (NASDAQ:CLPT – Get Rating) last posted its quarterly earnings data on Wednesday, March 1st. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. The firm had revenue of $5.17 million during the quarter, compared to analyst estimates of $5.19 million. ClearPoint Neuro had a negative net margin of 86.31% and a negative return on equity of 47.54%. As a group, research analysts anticipate that ClearPoint Neuro, Inc. will post -0.7 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, B. Riley reiterated a “buy” rating and set a $14.00 price target on shares of ClearPoint Neuro in a report on Thursday, February 16th.

ClearPoint Neuro Profile

(Get Rating)

Clearpoint Neuro, Inc engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system.